FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPRO	VAL
OMB Number:	3235-0287
Estimated average burde	en
hours per response:	0.5
	OMB Number: Estimated average burde

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Chodakewitz Jeffrey. (Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE (Street) BOSTON MA 02210 (City) (State) (Zip)							2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX] 3. Date of Earliest Transaction (Month/Day/Year) 02/02/2015 4. If Amendment, Date of Original Filed (Month/Day/Year)								S. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title Other (specify below) EVP GMDA, CMO S. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Ye						Execution Date,		·				urities Acquired (A) or led Of (D) (Instr. 3, 4 and		5. Amount of Securities Beneficially Owned Followi Reported		ities icially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount	(A) or (D)	Price		Trans	action(s) 3 and 4)		(1113411 4)	
Common)15	5			S ⁽¹⁾		300	D	\$108.64	(2)(3)	84,200		D						
Common Stock 02/02/201						5			S ⁽¹⁾		788	D	\$109.8	(3)(4)	83,412		D		
Common Stock 02/02/201						15			S ⁽¹⁾		100	D	D \$110.		85 83,312		D		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction 3A. I Exec (Month/Day/Year) if an		(e.g., p		alls,	5. Number of Derivative Securities Acquired (A) or Disposed		6. D	ions,	convertib rcisable and Date	f, or Benefic tible securities 7. Title and Amount of Securities Underlying Derivative Security (Inst and 4)		8. Price Derivative Securi (Instr.	ce of ative derivative Securities Beneficial Owned Following Reported	Following Reported	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	of (D) (Instr and 5	. 3, 4	Date Exe	e rcisable	Expiration Date	Title	Amount or Number of Shares	_		Transaction((Instr. 4)	s)		

Explanation of Responses:

- 1. Transaction made pursuant to Dr. Chodakewitz's company approved trading plan under Rule 10b5-1.
- 2. Open market sales reported on this line occurred at a weighted average price of \$108.64 (range \$108.30 to \$109.24).
- 3. Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- 4. Open market sales reported on this line occurred at a weighted average price of \$109.80 (range \$109.42 to \$110.37).

Remarks:

Omar White, Attorney-In-Fact 02/04/2015

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.